ADC Therapeutics SA announced the appointment of Jennifer Creel as Chief Financial Officer. Ms. Creel joins ADC Therapeutics from Celgene Corporation. Ms. Creel most recently served as Franchise Chief Financial Officer and Corporate Vice President, Global Finance & Business Planning at Celgene until its acquisition by Bristol Myers Squibb. During her 11 years at Celgene, Ms. Creel held multiple finance positions of increasing responsibility, including Vice President of Finance, Hematology & Oncology, and Executive Director, Global Business Planning & Analysis. Earlier in her career, Ms. Creel held finance roles at Watson Pharmaceuticals Inc. and Pfizer Inc. She holds an MBA from the University of Virginia and a BA in economics and French from The College of William and Mary.